Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
China: The Chinese patent (CN 101778608) expires December 2023, but China's regulatory approval process for peptide drugs is slower than the U.S
The same limitations apply to oral tirzepatide drops
Multivariate Hazard ratio (HR) was calculated with 95% confidence interval using multivariate Cox proportional hazards regression after adjustment for age, pT (Tumor size), pN (Regional lymph nodes), ER (Estrogen receptor), HER2 (Erb-B2 Receptor Tyrosine Kinase 2/HER2), tumor grade, patient age at diagnosis
Conversely, sunburn, herniated intervertebral discs, traffic accidents, and pneumonia were chosen as negative outcome controls
Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight)
US$ 20.69
US$ 28.79
US$ 20.57
US$ 20.13
US$ 21.55
